The being tested is an antiviral that has also been tried to treat Ebola in Africa.
The first clinical trial of the Remdesivir, which is experimentally used to treat COVID-19, did not show its effectiveness, the Financial Times reports, citing the who.
This is one of the that US President Donald Trump called “promising”. It is also included in the Ukrainian Protocol for the treatment of coronavirus.
A Chinese study found that Remdesivir, developed by the American company Gilead Sciences, did not improve the condition of patients or reduce the presence of the pathogen in the blood.
The study involved 237 patients.
158 patients took the, and 79 received standard placebo therapy. There was almost no difference.
A month later, 13.9% of patients who took the diet. Among those who received a placebo, 12.8% died.
News of the failure was posted in the world health organization’s clinical trial database, but it was later deleted.
A representative said that the information was uploaded too early by accident.
“The draft document for who was provided by its authors. It was accidentally posted on the site and removed as soon as the error was noticed.
The study is being reviewed and we are waiting for the final version before commenting, ” said Tarik Jasarevic, a who representative.
18 patients also had side effects. So people stopped using it.
Manufacturer Gilead Sciences noted that the report included “inappropriate research characteristics”.
“The important thing is that this study was terminated prematurely due to a small involvement, so it is not enough to draw statistically significant conclusions based on it.
Therefore, the results of the study are inconclusive, although trends in the data indicate a potential benefit from the , especially among patients treated in the early stages of the disease, ” the company said.
By this time, the use of Remdesivir in the treatment of coronavirus was based on studies that did not meet the scientific standards of randomization and the presence of a control group.
Remdesivir is an antiviral that has also been tested against Ebola in Africa, but there have been no significant results.